Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004-2012

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Morlat, Philippe ^a,b,c   Vivot, Alexandre ^c   Vandenhende, Marie Anne ^a,b,c   Dauchy, Frédéric Antoine ^c   Asselineau, Julien ^c   Déti, Edouard ^c   Gerard, Yann ^d   Lazaro, Estibaliz ^a,c   Duffau, Pierre ^c   Neau, Didier ^a,c   Bonnet, Fabrice ^a,b,c   Chêne, Geneviève ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d Observatoire de Dax   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; TENOFOVIR;

ADULT; AGE DISTRIBUTION; ANTIGEN DETECTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EXPOSURE; ETHNICITY; FEMALE; FOLLOW UP; FRANCE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADENINE; AGE FACTORS; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; ORGANOPHOSPHONATES; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEX FACTORS;

EID: 84878936689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066223     Document Type: Article

References (41)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266.
2. Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V, (2007) Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 4: e270 doi:10.1371/journal.pmed.0040270.
3. Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, et al. (2008) Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 47: 1449-1457 doi:10.1086/593099.
4. Bigé N, Lanternier F, Viard J-P, Kamgang P, Daugas E, et al. (2012) Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrol Dial Transplant 27: 1114-1121 doi:10.1093/ndt/gfr376.
5. Deti EK, Thiebaut R, Bonnet F, Lawson Ayayi S, Dupon M, et al. (2010) Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 11: 308-317.
6. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, et al. (2007) Chronic renal failure among HIV-1-infected patients. AIDS 21: 1119-1127 doi:10.1097/QAD.0b013e3280f774ee.
7. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, et al. (2008) Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 197: 1548-1557 doi:10.1086/587994.
8. Sorlí ML, Guelar A, Montero M, González A, Rodriguez E, et al. (2008) Chronic kidney disease prevalence and risk factors among HIV-infected patients. J Acquir Immune Defic Syndr 48: 506-508 doi:10.1097/QAI.0b013e31817bbecb.
9. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, et al. (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100 doi:-10.1111/j.1523-1755.2005.00365.x.
10. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004 (2007) MMWR Morb Mortal Wkly Rep. 56: 161-165.
11. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, et al. (2010) Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 1667-1678 doi:10.1097/QAD.0b013e328339fe53.
12. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, et al. (2002) Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61: 195-202 doi:10.1046/j.1523-1755.2002.00094.x.
13. Krawczyk CS, Holmberg SD, Moorman AC, Gardner LI, McGwin G Jr, (2004) Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS 18: 2171-2178.
14. Leport C, Bouteloup V, Rossert J, Garre M, Iordache L, et al. (2009) Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE. Clin Infect Dis 49: 1950-1954 doi:10.1086/648445.
15. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, et al. (2006) Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 43: 278-283 doi:10.1097/01.qai.0000243103.03265.2b.
16. Kiser J, Carten M, Aquilante C, Anderson P, Wolfe P, et al. (2007) The Effect of Lopinavir//Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients. Clin Pharmacol Ther 83: 265-272.
17. Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H, (2007) Effect of tenofovir on renal glomerular and tubular function. AIDS 21: 1483-1485 doi:[]10.1097/QAD.0b013e328216f15b [doi].
18. Goicoechea M, Liu S, Best B, Sun S, Jain S, et al. (2008) Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197: 102-108 doi:10.1086/524061.
19. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, et al. (2010) Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 53: 62-69 doi:10.1097/QAI.0b013e3181be6be2.
20. Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, et al. (2011) Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med 12: 4-13 doi:-10.1111/j.1468-1293.2010.00855.x.
21. Albini L, Cesana BM, Motta D, Focà E, Gotti D, et al. (2012) A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr 59: 18-30 doi:10.1097/QAI.0b013e31823a6124.
22. Young J, Schäfer J, Fux CA, Furrer H, Bernasconi E, et al. (2012) Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 26: 567-575 doi:10.1097/QAD.0b013e32834f337c.
23. Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, et al. (2012) Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS (London, England). doi:10.1097/QAD.0b013e328357f5ed.
24. Thiébaut R, Morlat P, Jacqmin-Gadda H, Neau D, Mercié P, et al. (2000) Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA). AIDS 14: 971-978.
25. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, et al. (2007) Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772 doi:10.1373/clinchem.2006.077180.
26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
27. Jones C, Roderick P, Harris S, Rogerson M, (2006) Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 21: 2133-2143 doi:10.1093/ndt/gfl198.
28. Buehring B, Kirchner E, Sun Z, Calabrese L (2011) The Frequency of Low Muscle Mass and Its Overlap With Low Bone Mineral Density and Lipodystrophy in Individuals With HIV-A Pilot Study Using DXA Total Body Composition Analysis. Journal of Clinical Densitometry. doi:10.1016/j.jocd.2011.10.003.
29. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, et al. (2009) Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 10: 329-336 doi:-10.1111/j.1468-1293.2008.00691.x.
30. De Beaudrap P, Diallo MB, Landman R, Guèye NF, Ndiaye I, et al. (2010) Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses 26: 1221-1227 doi:10.1089/aid.2009.0261.
31. Brennan A, Evans D, Maskew M, Naicker S, Ive P, et al. (2011) Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 25: 1603-1609 doi:10.1097/QAD.0b013e32834957da.
32. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, et al. (2012) Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26: 867-875 doi:10.1097/QAD.0b013e328351f68f.
33. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505 doi:10.1086/655681.
34. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, et al. (2008) The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22: 2155-2163 doi:[]10.1097/QAD.0b013e3283112b8e [doi].
35. Gupta SK, (2008) Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 22: 99-103 doi:10.1089/apc.2007.0052.
36. Dauchy FA, Lawson-Ayayi S, de La Faille R, Bonnet F, Rigothier C, et al. (2011) Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 80: 302-309 doi:[]10.1038/ki.2011.124 [doi].
37. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, et al. (2009) Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48: e108-16 doi:10.1086/598507.
38. Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, et al. (2012) Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 26: 1917-1926 doi:10.1097/QAD.0b013e3283574e71.
39. Gerstein HC, Mann JFE, Yi Q, Zinman B, Dinneen SF, et al. (2001) Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals. JAMA 286: 421-6 doi:10.1001/jama.286.4.421.
40. Gupta SK (2005) Tenofovir and changes in renal function. Clin Infect Dis 41: 570-1; author reply 571. doi:CID36718 [pii] 10.1086/432124.
41. Clark WF, Macnab JJ, Sontrop JM, Jain AK, Moist L, et al. (2011) Dipstick proteinuria as a screening strategy to identify rapid renal decline. J Am Soc Nephrol 22: 1729-1736 doi:10.1681/ASN.2010111217.